Author

L. Verschueren

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

B. De Clerck· 1 shared B. Voeten· 1 shared C. Buyck· 1 shared C. Van den Eynde· 1 shared C. Van Hove· 1 shared D. Bojkova· 1 shared D. De Pooter· 1 shared D. Jochmans· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

B. De Clerck

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Sustained liver HBsAg loss and clonal T and B cell expansion upon therapeutic DNA vaccination require low HBsAg levels

N. Conceicao-Neto, W. Pierson, M. Vacca, M. Beyens, B. De Clerck, L. Aerts, B. Voeten, D. De Pooter, L. Verschueren, K. Dockx, M. Vandenberk, E. De Troyer, K. Verwilt, C. Van Hove, M. Verslegers, , E. Van Gulck

This study shows that sustained HBsAg loss and immune cell expansion in the liver occur after therapeutic DNA vaccination in a mouse model when HBsAg levels are low.

bioRxiv · Sep 4, 2023Immunology

Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures

W. Chiu, L. Verschueren, C. Van den Eynde, C. Buyck, S. De Meyer, D. Jochmans, D. Bojkova, S. Ciesek, J. Cinatl, S. De Jonghe, P. Leyssen, J. Neyts, M. Van Loock, E. Van Damme

The paper develops a high-throughput screening assay to evaluate 5676 phase 1 compounds for in vitro anti-SARS-CoV-2 activity, identifying eight candidates but finding only remdesivir suitable for further clinical development.

bioRxiv · Feb 2, 2022Immunology